| Authors: |
Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Sigal D; Scripps Clinic and Scripps Cancer Center, La Jolla, CA., Varghese A; Memorial Sloan Kettering Cancer Center, New York, NY., Vaena D; West Cancer Center & Research Institute, Germantown, TN., Bai LY; China Medical University Hospital, Taichung, Taiwan., Chen MH; Taipei Veteran General Hospital, Taipei, Taiwan., Yeh CN; Chang Gung Memorial Hospital, Taipei City, Taiwan., Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Baysal MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Chakraborty A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee I; OBI Pharma Inc, Taipei City, Taiwan., Shia CS; OBI Pharma Inc, Taipei City, Taiwan., Ristoski K; OBI Pharma USA, Inc, San Diego, CA., Xu D; OBI Pharma USA, Inc, San Diego, CA. |
